ClinicalTrials.gg

Program

Ambroxol

Also written as “Ambroxol Spray”, “Ambroxol Hydrochloride” and “Ambroxol hydrochloride (Mucoangin?)”.

Its studies are mostly in Pharyngitis · Gaucher Disease · Parkinson Disease, led by 4 companies.

Furthest: phase 3, since Sep 7, 20057 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim30 open or runningphase 3since Sep 7, 2005Sep 7, 2005none ahead
Agyany Pharma20 open or runningphase 2since Nov 7, 2023Nov 7, 2023none ahead
Exsar10 open or runningphase 2since Oct 27, 2011Oct 27, 2011none ahead
Hanmi Pharmaceutical10 open or runningphase 1since Apr 5, 2012Apr 5, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2005First study: phase 3 study in PharyngitisNew to Boehringer IngelheimBoehringer Ingelheim · NCT00148499 · 751 enrolled · Romania, Ukraine
  2. Sep 3, 2007Phase 3 study in PharyngitisBoehringer Ingelheim · NCT00525044 · 249 enrolled · China
  3. May 16, 2011Phase 2 study in PharyngitisBoehringer Ingelheim · NCT01361802 · 494 enrolled · South Africa
  4. Oct 27, 2011Exsar's first study: phase 2 study in Gaucher DiseaseNew to ExsarExsar · NCT01463215 · 20 enrolled · United States
  5. Apr 5, 2012Hanmi Pharmaceutical's first study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01573663 · 21 enrolled · Korea, Republic of
  6. Nov 7, 2023Agyany Pharma's first study: phase 2 study in Parkinson DiseaseNew to Agyany PharmaAgyany Pharma · NCT06193421 · 46 enrolled · Israel
  7. Nov 21, 2025No phase study in Gaucher DiseaseAgyany Pharma · NCT07285369 · 12 enrolled · Pakistan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07285369Gaucher Disease · Pakistan–CompletedAgyany PharmaMar 30, 202612
NCT06193421Parkinson Disease · Israel2TerminatedAgyany PharmaMar 30, 202646
NCT01573663Healthy · Korea, Republic of1CompletedHanmi PharmaceuticalApr 201221
NCT01463215Gaucher Disease · United States2SuspendedExsarDec 201420
NCT01361802Pharyngitis · South Africa2CompletedBoehringer IngelheimAug 2011494
NCT00525044Pharyngitis · China3CompletedBoehringer IngelheimJan 1, 2008249
NCT00148499Pharyngitis · Romania, Ukraine3CompletedBoehringer IngelheimJun 2006751

How it is read

Names in the registry

  • “Ambroxol”, 4 entries
  • “Ambroxol Spray”, 3 entries
  • “Ambroxol Hydrochloride”, 1 entry
  • “Ambroxol hydrochloride (Mucoangin?)”, 1 entry
  • “Ambroxol and Levodropropizine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Ambroxol (Boehringer Ingelheim): development program | ClinicalTrials.gg